[Remote] Senior Cell Therapy Account Manager (New Jersey) at Arcellx

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Master’s or bachelor’s degree
5+ years of hematology/oncology therapeutic experience
Experience in cell therapy, immunotherapy, and/or multiple myeloma (strongly preferred)
Strong understanding of oncology market dynamics
Proven track record of meeting or exceeding sales objectives in complex, competitive, high-value therapeutic areas
Ability to manage large, strategic accounts and navigate complex academic hospital systems
Experience with new product launches

Responsibilities

Drive multiple myeloma CAR-T brand choice within authorized treatment centers and community-based accounts
Competitively sell Arcellx products through a deep knowledge of the multiple myeloma landscape and best-in-class clinical expertise
Effectively navigate complex account environments by identifying and understanding the needs and challenges of diverse stakeholders and collaborate with internal teams to provide targeted support
Integrate customer insights and analytical data to design and execute strategic account plans
Share relevant account and HCP insights with cross-functional and alliance partners
Support alliance partners to ensure the patient experience is positive and seamless
Equip ATC staff with CAR-T process training to eliminate barriers to use and optimize operational workflows
Operate in strict compliance with all laws, regulations, company policies, and ethical standards, including protection of patient-identifiable data

Skills

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free